Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Richard Walgren, MD, PhD, Crystal Dao, MA, Frederieke Kreisel, MD, Peter Westervelt, MD, PhD, Camille Abboud, MD, Timothy Graubert, MD, Amanda Cashen, MD, Geoffrey Uy, MD, Feng Gao, MD, John DiPersio, MD, PhD, Ravi Vij, MD

Blood (2007) 110 (11): 1451.

https://doi.org/10.1182/blood.V110.11.1451.1451

Published: 2007

Journal Articles

Generation of T reg -Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.

Jaebok Choi, PhD, Julie Ritchey, John DiPersio, MD, PhD

Blood (2007) 110 (11): 62.

https://doi.org/10.1182/blood.V110.11.62.62

Published: 2007

Journal Articles

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

John DiPersio, MD, PhD, Edward A. Stadtmauer, MD, Auayporn P. Nademanee, MD, Patrick Stiff, MD, Ivana Micallef, MD, J. Angell, MS, G. Bridger, PhD, Gary Calandra, MD, for the 3102 Investigators7

Blood (2007) 110 (11): 445.

https://doi.org/10.1182/blood.V110.11.445.445

Published: 2007

Journal Articles

A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Amanda Cashen, MD, Ajit Shah, PhD, Angela Helget, Laura Todt, Nicholas Fisher, John DiPersio, MD, PhD

Blood (2005) 106 (11): 1854.

https://doi.org/10.1182/blood.V106.11.1854.1854

Published: 2005

Journal Articles

Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.

Michael Rettig, PhD, Julie Ritchey, Julie Prior, David Piwnica-Worms, MD/PhD, Mark Bonyhadi, PhD, John DiPersio, MD/PhD.

Blood (2005) 106 (11): 5257.

https://doi.org/10.1182/blood.V106.11.5257.5257

Published: 2005

Journal Articles

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

Michael Rettig, PhD, Matthew Holt, Fulu Liu, MD, Julie Ritchey, Daniel Link, MD, Gary Bridger, PhD, John DiPersio, MD/PhD

Blood (2005) 106 (11): 5224.

https://doi.org/10.1182/blood.V106.11.5224.5224

Published: 2005

Journal Articles

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Aarati Rao, MD, Robert Hayashi, MD, William Grossman, MD, PhD, David Wilson, MD, PhD, Lolie Yu, MD, John DiPersio, MD, PhD, Yvonne Barnes, PNP, Shalini Shenoy, MD

Blood (2004) 104 (11): 1823.

https://doi.org/10.1182/blood.V104.11.1823.1823

Published: 2004

NARROW

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Generation of T reg -Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Email alerts

ASH Publications

American Society of Hematology

A Phase II Study of Intravenous Azacitidine Alone in Patients with Myelodysplastic Syndromes NCT00384956.

Generation of T reg -Like Cells from CD4+CD25- T Cells Via Epigenetic Modification Using a Demethylating Agent Decitabine.

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 (Plerixafor)+G-CSF vs. G-CSF+Placebo for Mobilization in Multiple Myeloma (MM) Patients for Autologous Hematopoietic Stem Cell (aHSC) Transplantation.

A Phase I Pharmacokinetic Trial of Decitabine Administered as a 3-Hour Infusion to Patients with Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS).

Comparison of the Proliferative Kinetics, GVHD Potential and GCV Sensitivity of Naive and Transduced and Selected Murine T Cells after Allogeneic BMT.

Evaluation of the Phenotype and GVHD-Inducing Potential of Splenic T Cells Isolated from G-CSF, AMD3100, or G-CSF and AMD3100 Pretreated Allogeneic Donors.

Reduced Intensity Conditioning Therapy Using Campath -1H Is Successful for Stem Cell Transplantation in Non-Malignant Disorders.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only